Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
Clin Lung Cancer
; 21(5): 395-406, 2020 09.
Article
em En
| MEDLINE
| ID: mdl-32505631
Non-small-cell lung cancer is a major cause of cancer morbidity and mortality worldwide, and these patients have traditionally had a grim prognosis. As our understanding of actionable molecular aberrations that drive oncogenesis has grown, so too has the number of available therapies with improved outcomes in selectively targeted patient populations. This review provides an overview of the clinical response of tumors harboring relatively rare oncogenic drivers to currently approved targeted agents and those in late-stage clinical development. Molecular testing methods available for screening for oncogenic drivers will be discussed.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Carcinoma Pulmonar de Células não Pequenas
/
Terapia de Alvo Molecular
/
Neoplasias Pulmonares
/
Mutação
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Clin Lung Cancer
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2020
Tipo de documento:
Article
País de publicação:
Estados Unidos